Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
Steeped in inequities that include formidable barriers to basic health services for multitudes of its most vulnerable, marginalized and neglected people, the country leading global HIV […]
In the six weeks before South Africa responded its first diagnoses of COVID-19 with the start of physical distancing measures, more than 47,000 people on average […]
CDC urges physicians, parents to be on lookout for AFM, a polio-like illness seen predominately in children
With 2018 data showing highest incidence acute flaccid myelitis since monitoring began, officials say awareness, recognition of rare life threatening condition will be crucial to early […]
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]